Abstract. Phosphatase of regenerating liver (PRL)-3 was identified as a molecule associated with liver metastasis in colorectal cancer (CRC), although its precise causative role in distant metastasis remains elusive from a clinical point of view. The aim of this study was to promote the mechanistic insight of PRL-3 involvement in liver metastasis in CRC. One hundred and seven CRC patients with resection of the primary lesions were studied for clinicopathological and prognostic association with PRL-3 and were evaluated by immunohistochemistry in univariate and multivariate analyses. Intense immunostaining of PRL-3 was found in Dukes' A (0/26), Dukes' B (0/30), Dukes' C (18/30) and Duke's D (20/21) although the PRL-3 expression could not predict metachronous liver metastasis (MLM) in Dukes' C patients. PRL-3 expression showed an inverse correlation of prognosis in a univariate prognostic analysis (P<0.0001), though a multivariate assay failed to demonstrate PRL-3 relevance as an independent prognostic factor. PRL-3 expression was closely associated with classic prognostic factors such as the pN factor (P<0.0001), H factor-synchronous liver metastasis (SLM) (P<0.0001), pT factor (P=0.0002), preoperative CEA (P<0.0001) and preoperative CA19-9 (P<0.0001). Multivariate logistic regression analysis of PRL-3 expression revealed that the pN factor (P<0.0001), CEA (P<0.0001) and CA19-9 (P<0.0001) were finally remnant as an independent association with PRL-3. However, the H factor (SLM) was eliminated. Our data suggested that liver metastasis by PRL-3 is putatively mediated through lymph node metastasis and elevated tumor markers in the serum and the PRL-3 expression may not represent a direct causative mechanism of liver metastasis.
Introduction
Phosphatases and kinases are the cellular signal transduction enzymes that control protein phosphorylation. Protein tyrosine phosphatases (PTPs) play functional roles in regulating diverse proteins, which participate essentially in every aspect of cellular physiological and pathogenic processes (1) . Phosphatase of regenerating liver (PRL)-1, -2 and -3 represents a novel class of PTPs superfamily members in possessing a unique COOH-terminal prenylation motif with a PTP active site signature sequence CX5R (2) . PRL phosphatases were found to be associated with the early endosome and plasma membrane in their prenylated state, while nuclear localization of these enzymes may occur in the absence of prenylation (3) . Each of the proteins are of ~20 kD and share 75% amino acid sequence similarity. PRL-1 was originally identified as an immediate early gene whose expression was included in mitogen-stimulated cells and regenerating liver (4) . Overexpression of PRL-1 and PRL-2 transformed mouse fibroblasts and hamster pancreatic epithelial cells in culture and promoted tumor growth in nude mice, suggesting that it may participate in tumorigenesis (2, 5) .
Colorectal cancer (CRC) incidence and mortality has increased dramatically over the last decades in many regions and has become the second most common cancer worldwide. Metastasis of CRC in the liver is often responsible for the highest mortality rate and involvement of liver metastasis is an important prognostic factor for CRC. Mechanisms of liver metastasis of CRC are not fully clarified because of the involvement of multiple steps with the accumulation of an altered expression of a number of different genes. To gain insights into the molecular basis for metastasis, Saha et al compared the global gene expression profile of metastatic CRC with that of primary cancers, benign colorectal tumors, and normal colorectal epithelium (6) . Overexpression of PRL-3 was elucidated to be associated with human CRC metastasis, and in 3 of 12 metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9 chromosome 8q24.3 (6, 7) . These data suggested that the PRL-3 gene is important for colorectal cancer metastasis and provide a new therapeutic target of these intractable lesions.
However, the precise clinicopathological role of PRL-3 still remains elusive even in CRC from a prognostic point of view. Table I . CRC was divided into either colon cancer or rectal cancer. Colon cancer consisted of cecal, ascending, transverse, descending, and sigmoid colon cancer. pT was designated as the following according to the 6th Japanese Classification of Colorectal Cancer (JCCC); pT0 (mucosal invasion), pT1 (submucosal invasion), pT2 (muscuralis propria invasion), pT3 (subserosal invasion or serosal exposure) and T4 (invasion to the surrounding organs). pN factor, H factor, LM factor and P factor represented lymph node metastasis, hepatic metastasis (synchronous liver metastasis: SLM), lung metastasis and peritoneal dissemination, respectively.
Materials and methods

Preparation
Immunohistochemical study. We examined PRL-3 immunostaining in 5 liver metastatic lesions of CRC and 5 normal colorectal mucosal tissues in order to confirm a positive and negative control of PRL-3, respectively, with 4 kinds of antibody #1 anti-human/-mouse/-rat PRL-3 antibody Clone 334402 (mouse monoclonal IgG 2B , R&D Systems Inc., Minneapolis, MN), #2 anti-PRL-3 antibody GB63023 (rabbit monoclonal, Genesis Biotech Inc., Taipei, Taiwan), #3 antihuman/-mouse PRL-3 antibody (mouse monoclonal IgG 1 , Abgent Inc., San Diego, CA) and #4 anti-PRL-3 antibody (rabbit polyclonal, Zymed Laboratories Inc., South San Francisco, CA). Among them, #1 showed much more remarkable contrasts between the positive and negative controls when an antibody was 20-fold diluted (in a comparison with 50-and 100-fold dilution of #1 or other antibodies). Under the best optimized conditions, 5 liver metastatic lesions of CRC and 5 normal colorectal mucosal tissues were all positive and negative, respectively. We then applied this immunohistochemical technique to 107 paraffinembedded CRC. We scored the expression as negative when <10% of the carcinoma cells were stained in an examined area of a specimen. Table I ) and revealed that PRL-3 expression is significantly involved in classic prognostic factors such as pT (P=0.0002), pN (P<0.0001), histology (P=0.0002), P factor (P=0.06), preoperative CEA (P<0.0001), preoperative CA19-9 (P<0.0001) and Dukes stage (P<0.0001).
Results
PRL-3 immunostaining identified in
We performed a univariate prognostic analysis using the log-rank test and revealed that a poor prognosis of CRC patients was significantly associated with pN factor (P<0.0001), histology (P=0.019), H factor (SLM) (P<0.0001), LM factor (P=0.035), P factor (P<0.0001), preoperative serum CEA value (P<0.0001) and preoperative serum CA19-9 value (P=0.0007). We could not assess the prognostic relevance according to pT and Dukes staging using StatView 5.0 software, since there was no censored cases with T0, 1, 2 and Dukes A CRC patients among cases we examined. For the total 107 CRC, intense immunostaining of PRL-3 showed a remarkable prognostic difference as compared with none to weak immunostaining of PRL-3 (P<0.0001, Fig. 2A ).
Multivariate prognostic analysis revealed that PRL-3 involvement in SLM may be mediated by lymph node metastasis and elevated tumor markers.
In the current study, we could not assess the prognostic relevance according to pT factor as stated earlier and our multivariate hazard proportional model was restricted to the 85 pT3,4 CRC, which showed that PRL-3 could not be an independent prognostic factor and that finally remnant independent prognostic factors were H factor (SLM) (HR=10.0; p<0.0001), preoperative CA19-9 (HR=3.89; p=0.01), pN (HR=3.70; p=0.028) and preoperative CEA (HR=2.73; p=0.02) (Table II) . To reveal the reason for elimination of PRL-3 expression as an independent prognostic factor, we performed a multivariate logistic regression analysis as to PRL-3 immunostaining for each of the univariate prognostic factors with p<0.1 and revealed that PRL-3 expression was independently associated with lymph node metastasis (RR: relative risk=5.78; p<0.0001), preoperative CEA (RR=5.27; p<0.0001) and preoperative CA19-9 (RR=3.93; p<0.0001), while H factor was eliminated as an independent association with PRL-3 expression. The multivariate analyses led us to speculate that PRL-3 involvement in SLM may be mediated by lymph node metastasis and elevated tumor markers (Fig. 3) .
Relationship of PRL-3 immunostaining to metachronous liver metastasis (MLM) and prognosis with Dukes C CRC patients.
We then examined the relationship between PRL-3 immunostaining and MLM using Dukes C CRC patients, since MLM occurred largely among Dukes C patients and rarely among Dukes B and A patients. Among 30 Dukes C CRC patients examined in this current study, MLM was found in 16 cases (53%) during a follow-up course. A PRL-3 immunostaining pattern did not have any value in predicting MLM in Dukes C CRC patients as follows: the patterns subdivided into intense/weak/none to faint immunostaining of PRL-3 in absence and presence of MLM are 9/2/3 cases and 9/4/3 cases, respectively (no significant difference). As reflected this finding, PRL-3 immunostaining did not have any prognostic value if restricted to Dukes C CRC patients (Fig. 2B) . These findings may indicate that PRL-3 expression Table I . Relationship between clinicopathological factors and PRL-3 immunostaining intensity and survival in 107 patients with CRC.
- is not directly involved in liver metastasis, even though it is either synchronous or metachronous.
Discussion
In this study, PRL-3 is more closely associated with lymph node metastasis than SLM and univariate PRL-3 association with SLM is deemed just to reflect unique biological characters of CRC. PRL-3 is independently associated with lymph node metastasis, CEA and CA19-9 (Table III) , which were in turn an independent prediction of SLM by a multivariate logistic regression analysis (data not shown). A large portion of SLM occurs in patients with lymph node metastasis (18 out of 21 Dukes D cases). These findings indicated that PRL-3 is involved in SLM through lymph node metastasis and elevated tumor markers. Kato et al proposed PRL-3 as being a potential for the prediction of MLM in CRC (8) . However, the prediction value becomes effective for clinical use if its value is restricted to Dukes C patients, since MLM is very rare in Dukes A and B CRC patients. As our data are based on a small number of patients in Dukes C (n=30), we did not expect a good potential of PRL-3 expression predicting MLM (Fig. 2B ). Taking the two negative aspects of SLM and MLM as to PRL-3 expression into account, we had to conclude that PRL-3 expression is significantly involved in metastatic potential of lymph nodes, though not directly in liver metastasis. The Vogelstein lab initially identified PRL-3 as a consistent association with liver metastasis (6,7), where they reported that PRL-3 expression is found in all the lymph node metastasis of CRC by in situ hybridization (n=4) (7). This finding was validated by a recent immunohistochemical analysis in CRC (9) . Furthermore, reports that PRL-3 could reflect lymph node metastasis have been increasing even in other organs such as gastric cancer (10,11) and breast cancer (12) . In gastric cancer, PRL-3 expression was detected in 68% of primary lesions (with nodal metastasis 81.5%, without nodal metastasis 50%; p=0.004) and the incidence of PRL-3 expression in lymph node metastasis was significantly higher than that in primary gastric cancers (p<0.001). Moreover, PRL-3 expression was closely associated with lymphatic invasion (p=0.002), extent of lymph node metastasis (p=0.002) and tumor stage (p=0.045), which suggested that PRL-3 expression may play a significant role in the invasion and metastasis of gastric carcinoma. Lymph node metastasis is one of the major concerns in the cancer research field, since the metastasis to lymph nodes is essential for cancer development. Several microarray studies profiling the expression of cancer tissues remains unresolved for bona fide therapeutic target molecules involved in lymph node metastasis (13, 14) . Hence we are now proposing that PRL-3 may surrogate the lymph node metastatic phenotype for molecular insight or tumor maker development. A PRL-3 knock-down may elucidate an important mechanism of lymph node metastasis or identify markers of lymph node diseases.
Notably, alterations of CA19-9 and CEA in the preoperative serum were closely associated with PRL-3 expression status independently of lymph node metastasis (Fig. 3) . This is the first report in which an oncogenic molecule was associated with the serum level of CEA and CA19-9. It Table I . Continued.
-
------------------------------------------------------------------------------------------------------------------------------------------------PRL-3 staining (%) ------------------------------------------------------
Number (%) None or faint (n=54)
Weak (n=15) Intense (n=38) P-value DSS (5-year) 
DSS, disease-specific survival; NS, not significant; NA, not assessible; SLM, synchronous liver metastasis and CEA carcinoembryonic antigen.
is worth noting that cases with all the 3 positive parameters were only found in CRC with intense PRL-3 (see green box in Fig. 3 ) (p<0.0001). Cases with at least 2 positive parameters were recognized in 30 (79%) out of 38 intense PRL-3 cases, while in 2 (13%) out of 15 weak PRL-3 cases and 3 out of 54 none to faint PRL-3 cases (6%) (p<0.0001) (see blue green box in Fig. 3 ). These findings suggested that PRL-3 affects positivity of at least 2 factors among the three independent prognostic factors (lymph node metastasis, preoperative CEA and preoperative CA19-9) (Table II) .
Prognostic value of serum CEA or CA19-9 has become evident, while it remains controversial whether it is causative or results in tumor progression (15) . Previous basic research supported a novel notion of tumor-induced immune suppression and has proven to be at least partially mediated by CEA and CA19-9. CEA molecules which shed from the cancer cell surface are phagocytosed by the macrophage in the liver and activate for the release of various cytokines so as to make the environment suitable for the implantation of metastatic tumors (16, 17) . However, CA19-9 is a glycoform epitope, which is supposed to be abundantly expressed on the surface of O-type mucin such as MUC1 and is supposed to Table II . A multivariate analysis of factors associated with disease-specific survival. 
HR, hazard ratio; CI, confidence interval; P, peritoneal dissemination and NS, not significant. Table III . Factors associated with PRL3 immunostaining on multivariate logistic-regression analysis. be evident after transformation (18) . Such malignant mucin could induce COX2/PGE2 production in macrophages in the tissues (19) or even in the blood (20) and therefore serum CA19-9 is associated with serum PGE2 in gastrointestinal cancer (20) . It appears that COX-2/PGE2 induced via mucins represented by the CA19-9 epitope could be causative for tumor-induced immune suppression. These findings suggested that elevated tumor markers associated with PRL-3 may involve metastatic disease development of CRC through immune suppression.
PRL phosphatases constitute a novel class of small (20 kDa), prenylated phosphatase with oncogenic activity and represent a new therapeutic target. For angiogenic or metastatic ability, a causative role of PRL-3 phosphatase activity was confirmed (21) (22) (23) . Hence, the catalytic domain of PRL-3 could serve as an ideal therapeutic target for drug development in blocking the spread of CRC. Kozlov et al presented the solution structure of PRL-3, the first structure of a PRL-3 phosphatase and identified a potential regulatory role of Cys (49) that forms an intramolecular disulfide bond with the catalytic Cys (104), even under mildly reducing conditions (24) . Recently, the first report on PRL-3 inhibitors was very promising for the target therapy of CRC, isolated from natural sources as two biflavonoids, ginkgetin and sciadopitysin, from the MeOH extract of the young branches of Taxus cuspidate, which inhibited phosphatase of regenerating liver-3 (PRL-3) with IC 50 values of 25.8 and 46.2 μM, respectively (25) .
In conclusion, our current research identified four independent prognostic factors, SLM-H factor, preoperative CEA, preoperative CA19-9 and lymph node metastasis (Table II) and elucidated the relationship between PRL-3 expression and these prognostic factors. Our conclusion is that PRL-3 is associated with SLM, however, liver metastasis by PRL-3 is mediated by lymph node metastasis and elevated tumor markers and thereafter we interpret that lymph node metastasis and tumor-induced immune suppression may be needed for distant metastasis. Such a relevant relationship of prognostic factors may be a clue for an actual therapeutic strategy and PRL-3 inhibition could be promising in CRC.
